ProSpare reduces anorectal dose during postoperative prostate radiotherapy in the randomized POPS trial
ProSpare reduced anorectal dose and showed lower grade ≥1 bowel toxicity at 18 weeks, while the trial's primary two-year endpoint remains pending.